Physician profile
Nathan J Wright
NPI 1093796534
$1,641.04
in general payments reported to CMS, 2019-2025
34 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $71.52 · 2021: $217 · 2022: $273 · 2023: $263 · 2024: $226 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $164.75 | 2021-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $110.52 | 2019-2025 | |
| Novo Nordisk INC | $101.48 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $99.27 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $97.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $91.34 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $85.14 | 2022-2023 | Yupelri |
| Abbvie INC. | $82.02 | 2021-2025 | |
| Corcept Therapeutics | $77.92 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $68.90 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $64.19 | 2025 | Rexulti |
| Evoke Pharma, INC. | $63.64 | 2021-2024 | Gimoti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.72 | 2022-2024 | Jardiance, Synjardy |
| Inspire Medical Systems, INC. | $43.58 | 2025 | Inspire |
| Exact Sciences Corporation | $42.93 | 2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.81 | 2019-2024 | Xifaxan |
| Eisai INC. | $33.75 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $32.29 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.04 | 2023 | Oxlumo |
| Lilly USA, LLC | $25.40 | 2020-2024 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $21.40 | 2025 | Watchman Flx |
| Xeris Pharmaceuticals, INC. | $20.23 | 2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $20.08 | 2025 | Voquezna |
| Amarin Pharma, INC. | $18.55 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.40 | 2022 | |
| Chiesi USA, INC. | $18.23 | 2024 | Cleviprex |
| Allergan, INC. | $18.20 | 2019 | |
| Dexcom, INC. | $16.75 | 2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $15.01 | 2022 | |
| Tandem Diabetes Care, INC. | $14.86 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $14.10 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.96 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $13.03 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.